GSK’s Shingrix crowds out Merck in U.S. shingles vax market by Angus Liu Wednesday, April 11, 2018 GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.
GlaxoSmithKline's Shingrix recommended in Europe by Eric Sagonowsky Friday, January 26, 2018 After picking up key regulatory nods in the U.S., GlaxoSmithKline’s Shingrix is well on its way to expanding its reach into Europe.
CDC panel recommends GSK's Shingrix over older Merck shot by Eric Sagonowsky Wednesday, October 25, 2017 The CDC committee in charge of vaccination policy in the U.S. endorsed GlaxoSmithKline's Shingrix over the older shot, Merck's Zostavax.
FDA panel unanimously endorses Glaxo's Shingrix by Eric Sagonowsky Wednesday, September 13, 2017 Marking a big step in its march toward potential approval, GlaxoSmithKline’s shingles vaccine candidate Shingrix won the support of an FDA panel.
Patients allege they suffered injuries from Zostavax by Eric Sagonowsky Friday, July 21, 2017 U.S. Merck's shingles vaccine Zostavax faces a growing challenge in court.
GSK's Shingrix passes revaccination test by Eric Sagonowsky Thursday, June 22, 2017 Shingrix met its goal in a study examining whether it can protect older adults who previously received Merck’s Zostavax.
Merck hopes new Zostavax ad can scare up adult vaccination rates by Carly Helfand Monday, November 21, 2016 It wasn’t long ago that Merck’s Zostavax DTC marketing efforts included sporty, comedic spots. Its newest effort couldn’t be more different.
With first Shingrix application, GSK advances toward $1B market duel by Eric Sagonowsky Monday, October 24, 2016 Planning to challenge an entrenched product from Merck, GlaxoSmithKline on Monday filed the first licensing application for its shingles vaccine, Shingrix.
